MK-0752 is a γ-secretase inhibitor that suppresses Notch signaling and exhibits neuroprotective and anticancer chemotherapeutic activities. This compound decreases the formation of amyloid-β (Aβ) plaques. MK-0752 is in clinical trials as a potential treatment for brain and CNS-centric cancers.
| Cas No. | 471905-41-6 |
|---|---|
| Purity | ≥98% |
| Formula | C21H21ClF2O4S |
| Formula Wt. | 442.90 |
| IUPAC Name | 3-{cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl}propanoic acid |
| Appearance | Yellow crystal powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | M4200 Info Sheet PDF |
|---|
Hoffman LM, Fouladi M, Olson J, et al. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug;31(8):1283-9. PMID: 25930724.
Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008;8(1):17-33. PMID: 18220929.
